Mogamulizumab (Moga) is a humanized defucosylated anti-CC chemokine receptor 4 (CCR4) monoclonal antibody that markedly enhances antibody-dependent cellular cytotoxicity. Moga is effective for newly diagnosed and previously treated CCR4-positive ATLL. 4, 5 Therefore, Moga-containing induction therapy may lead to better disease control at the time of allo-HSCT. CCR4 is also expressed on regulatory T cells (Tregs) that induce anergic and suppressive allogeneic responses. 6 Decreased Treg activity mediated by Moga may be associated with an increased frequency of severe GvHD. However, little information exists regarding the effects of Moga in allo-HSCT in ATLL patients.
We retrospectively analyzed four patients with ATLL who received Moga-containing induction therapy followed by unrelated bone marrow transplantation (uBMT) at the National Kyushu Cancer Center between 2012 and 2013. This study was approved by the local institutional review board. All patients were treated with the EPOCH 7 -like regimen (modified (m)EPOCH) administered as follows: etoposide (50 mg/m 2 /day), doxorubicin (10 mg/m 2 /day), and vincristine (0.5 mg/day) each given as a continuous 96-h infusion on days 1-4. In addition, prednisolone (40 mg/m 2 /day) was given orally on day -4, then tapered and stopped on day 7 and IV carboplatin (target area under the curve of 3 mg/mL/min, using Calvert's formula 8 ) on day 6. Moga (1 mg/kg) was administered after at least a 1-week interval when induction chemotherapy was considered insufficient to achieve a durable response (for example, PR or better). The interval and frequency of Moga were based on each physician's judgment. All patients received an uBMT from an HLA-identical donor, using reduced-intensity conditioning consisting of fludarabine (30 mg/m 2 /day, days − 7 to − 2)/busulfan (3.2 mg/kg/day, days − 5 to − 4) with 2 Gy TBI. GvHD prophylaxis consisted of tacrolimus and short-term methotrexate.
A 56-year-old male was referred to our hospital because of systemic lymphadenopathy and acute pancreatitis caused by a splenic tumor. He was diagnosed with lymphoma-type ATLL; he received one cycle of a dose-reduced CHOP-like regimen followed by four cycles of mEPOCH and achieved PR. However, 1 month later, the disease progressed and he was treated with mEPOCH together with Moga (on day − 38). The size of the lymph nodes decreased after administration of Moga, and PR was achieved again. He received oral chemotherapy comprised of sobuzoxane and etoposide 9 for disease control and underwent uBMT. Neutrophil (40.5 × 10 9 /L) and platelet (42 × 10 9 /L) engraftment and complete donor chimerism were achieved on days 12, 20 and 28, respectively. On day 31, he developed a skin rash and was diagnosed with grade I acute GvHD (aGvHD). Oral betamethasone (1 mg/day) was administered and the clinical symptoms improved. However, the computed tomography (CT) scan on day 45 demonstrated enlargement of the splenic tumor and he received palliative radiotherapy. On day 112, he developed grade II intestinal aGvHD. Although administration of methylprednisolone (mPSL; 2 mg/kg/day) resulted in clinical improvement of GvHD, ATLL progressed rapidly. He received oral chemotherapy owing to poor performance status. Tacrolimus and mPSL were tapered and discontinued to induce graft-versus-ATLL effect. However, he died of ATLL on day 191.
A 61-year-old female with cervical lymphadenopathy and abnormal peripheral lymphocytes was diagnosed with acutetype ATLL. She received two cycles of a modified LSG15 regimen 1 and was transferred to our hospital. She received four cycles of mEPOCH and achieved PR. Because her peripheral abnormal lymphocytes persisted, she received two doses of Moga on days − 43 and − 37. After that, her peripheral abnormal lymphocytes disappeared and she underwent uBMT in CR. Neutrophil and platelet engraftment and complete donor chimerism were achieved on days 16, 23 and 32, respectively. On day 18, she developed a skin rash. She was diagnosed with grade II aGvHD, and administration of mPSL (2 mg/kg/day) was started. Although her symptoms temporarily improved, we could not taper immunosuppressant therapy owing to persistent aGvHD. On day 98, severe diarrhea began. A colonic mucosa biopsy confirmed the diagnosis of grade III aGvHD. Mycophenolate mofetil was additionally administered, but her GvHD did not respond to these therapies. On day 200, she developed rapidly progressive hemiplegia and died on day 201. A CT scan showed hemorrhagic infarction in the temporal lobe. An autopsy revealed widespread fungal microemboli in the cerebral vessels, and no ATLL cells were observed. We concluded that she died of fungal infection.
A 49-year-old male with enlarged tonsils and cervical lymph nodes and abnormal peripheral lymphocytes was diagnosed with acute-type ATLL. He received five cycles of mEPOCH. Four doses of Moga were administered during the second and third cycles of mEPOCH (on days − 142, − 128, − 114 and − 100). He achieved CR before uBMT, but Moga was discontinued because of a Mogainduced severe skin rash. Neutrophil and platelet engraftment and complete donor chimerism were achieved on days 23, 37 and 62, respectively. On day 26, he developed a skin rash and was diagnosed with grade II aGvHD, which was well controlled with topical steroid ointment. However, he began to complain of fatigue, and the CT scan on day 56 demonstrated systemic lymphadenopathy, pathologically confirmed as ATLL relapse. In addition to rapid tacrolimus taper, he received one cycle of mEPOCH. On day 74, his level of consciousness diminished progressively, and the CT scan demonstrated a mass in the pyramidal tract. He was treated with whole brain irradiation and three doses of donor lymphocyte infusion, which showed limited effect. He died of ATLL on day 147.
A 63-year-old male with erythema and peripheral abnormal lymphocytes was diagnosed with acute-type ATLL. He received six cycles of mEPOCH with three doses of Moga (on days − 150, − 136 and − 122). Although the skin lesion disappeared, abnormal peripheral lymphocytes persisted after the induction therapy, and PR was achieved at the time of uBMT. Neutrophil and platelet engraftment was achieved on days 18 and 30. On day 38, complete donor chimerism was observed in his peripheral blood, and thus CR was achieved. On day 29, he developed a skin rash and was diagnosed with grade II aGvHD. Administration of prednisolone (1 mg/kg/day) resulted in alleviation of symptoms, but he developed grade III intestinal aGvHD soon after the discontinuation of prednisolone, which led us to resume prednisolone treatment. Although he subsequently suffered repeated infectious episodes, it was not possible to cease immunosuppressant therapy completely owing to persistent chronic GvHD. He is alive in CR 650 days after the uBMT.
The clinical course of each of the four cases is summarized in Figure 1 .
Here we have described four patients with ATLL who underwent uBMT from HLA-identical donors after Moga-containing induction treatment. The median duration from the last Moga administration to uBMT was 78.5 days (range: 38-122 days). All patients achieved CR or PR at the time of uBMT and durable donor chimerism was attained. Grades II-IV aGvHD were observed in all patients, and Case 4, who survived for 41 year after the uBMT, suffered extensive chronic GvHD.
Several studies have demonstrated that Tregs limit lethal GvHD in murine models. 10 In humans, in vivo CD25 depletion using an immunotoxin after allo-HSCT led to an increased aGvHD owing to elimination of Tregs. 11 Furthermore, impaired reconstitution of Tregs after allo-HSCT is associated with development of chronic GvHD. 12 Therefore, Tregs are considered to have a pivotal role in the pathogenesis of GvHD.
There are only a few published case reports describing administration of Moga for a short time before treatment with allo-HSCT. Motohashi et al. 13 reported a patient with primary refractory ATLL who achieved CR after being treated with Moga before receiving uBMT from a 2-HLA-mismatched donor. The patient only developed grade I aGvHD, possibly because he received rabbit antithymocyte globulin for GvHD prophylaxis. In contrast, Ito et al.
14 reported an ATLL patient who relapsed after umbilical cord blood transplantation and was successfully treated with Moga, although he developed grade II aGvHD.
A phase II study found that the mean half-life of Moga was 422 ± 147 h, and the number of peripheral blood Tregs was reduced for at least 4 months after the eighth Moga infusion. 4 These results suggest that Moga administered before allo-HSCT can remain biologically active in patients for a long period of time.
Residual Moga may affect the number of Tregs in the graft and also the differentiation and expansion of Tregs from donor T cells. The reduced number of Tregs may result in the increased frequency and severity of episodes of GvHD and lead to an unfavorable outcome, even if a certain amount of graft-versus-ATLL 15 was obtained. Although the number of cases is too small to yield definitive conclusions, the deleterious effect of Moga used in the allo-HSCT setting should be noted.
Additional large-scale studies that use standardized treatment/ monitoring protocols (for example, measurement of circulating Tregs and serum Moga concentrations) are needed to identify the optimal timing and dosage of Moga, the conditioning regimen and GvHD prophylaxis for allo-HSCT candidates who have ATLL. 
